Evidence map›Paper›PMID 41082338›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Engineering Metal-Organic-Framework-Based STING Nanoagonists for PROTAC-Enhanced Cancer Chemo-Metalloimmunotherapy.

Zhenzhen Chen, Zhe Feng, Siyuan Wang, Jingjing Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhenzhen ChenState Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, 210023, China.
Zhe FengState Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, 210023, China.
Siyuan WangState Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, 210023, China.
Jingjing ZhangState Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, 210023, China.ORCID https://orcid.org/0000-0002-1041-793X

Funding

Fundamental Research Funds for the Central Universities 2024300408National Natural Science Foundation of China 22274072Natural Science Foundation of Jiangsu Province BK20242022State Key Laboratory of Analytical Chemistry for Life Science 5431ZZXM2505
6 · The paper itself

Abstract

Chemo-metalloimmunotherapy is emerging as a promising strategy for cancer treatment by integrating chemotherapy-induced immunogenicity with metal ion-mediated immune activation. However, its efficacy is hampered by chemoresistance and immune escape driven by PD-L1 upregulation. Here, a multifunctional manganese-based metal-organic framework nanoplatform (Mn-CDDP-dBET6@CM) is reported that integrates metalloimmunotherapy, chemotherapy, and Proteolysis-targeting chimera (PROTAC) -mediated epigenetic modulation for enhanced cancer treatment. This system co-delivers Mn

Indexed as

ImmunotherapyMembrane ProteinsMetal-Organic FrameworksNeoplasmsAnimalsAntineoplastic AgentsCell Line, TumorCisplatinHumansMiceSTING ProteinTumor MicroenvironmentAntineoplastic AgentsCisplatinMembrane ProteinsMetal-Organic FrameworksSTING1 protein, humanSTING Proteincancer therapychemotherapymetalloimmunotherapyPROTACSTING activation

Identifiers

PMID41082338
PMCPMC12786333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.